CSIMarket Company Name, Ticker, Customers, else..
 
Immunic Inc   (NASDAQ: IMUX)
 

Immunic Inc's Suppliers Performance

IMUX's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
IMUX Costs vs Sales of Suppliers Growth

• More on IMUX Suppliers






Immunic Inc's Comment on Supply Chain


The company utilizes third-party contract manufacturers for producing and formulating drug supplies required for preclinical studies and clinical trials. This dependence presents risks including production delays, manufacturing defects, staffing challenges, shifts in priorities, financial instability of manufacturers, and potential acquisitions or exclusive agreements with competitors. The manufacturing facilities operated by these contractors must undergo FDA inspection following NDA submission and adhere to current Good Manufacturing Practices (cGMP) and other regulatory standards. The company does not oversee the manufacturing processes or daily regulatory compliance of these third parties. Noncompliance could result in manufacturing suspension or revocation of approvals, negatively impacting the company's operations. Furthermore, third-party contractors may discontinue their services for financial or business reasons, potentially increasing costs and delaying drug development programs.

Immunic Inc's Comment on Supply Chain


The company utilizes third-party contract manufacturers for producing and formulating drug supplies required for preclinical studies and clinical trials. This dependence presents risks including production delays, manufacturing defects, staffing challenges, shifts in priorities, financial instability of manufacturers, and potential acquisitions or exclusive agreements with competitors. The manufacturing facilities operated by these contractors must undergo FDA inspection following NDA submission and adhere to current Good Manufacturing Practices (cGMP) and other regulatory standards. The company does not oversee the manufacturing processes or daily regulatory compliance of these third parties. Noncompliance could result in manufacturing suspension or revocation of approvals, negatively impacting the company's operations. Furthermore, third-party contractors may discontinue their services for financial or business reasons, potentially increasing costs and delaying drug development programs.







IMUX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Immunic Inc 451.50 0.00 -111.57 85
SUBTOTAL 0.00 0.00 0.00 -


Sources: Immunic Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Immunic Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.